Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CMC2 pseudogene 1 (CMC2P1) is a processed pseudogene derived from the ancestral CMC2 gene. Pseudogenes such as CMC2P1 typically arise from gene duplication or retrotransposition events and lack protein-coding capability due to mutations or loss of regulatory elements[2]. These genes do not encode functional proteins and are not considered classic molecular targets for drug development or therapy. While certain pseudogenes sometimes function as regulatory RNAs, sequestering microRNAs or modulating gene expression, there is no evidence in the literature indicating CMC2P1 has a specific functional or disease-related role[2]. In summary, CMC2P1 is not a protein-coding gene, receptor, enzyme, or therapeutic target. The entry “CMC2P1” is likely included in certain gene lists for completeness but should not be considered an actionable molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CMC2 pseudogene 1 (CMC2P1).